Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

padeliporfin 5Nivolumab 3vedolizumab 2atezolizumab 2anlotinib 2Therapeutics 2Surveys and Questionnaires 2Riluzole 2Radiotherapy 2LDP-02 2Ipilimumab 2Infliximab 2Immunoglobulin G 2Genetic Testing 2Fecal Microbiota Transplantation 2Disulfides 2Carboplatin 2CT-P13 2tislelizumab 1relatlimab 1prednylidene 1pembrolizumab 1palladium-bacteriopheophorbide 1olaparib 1niraparib 1ixabepilone 1ferumoxtran-10 1enfortumab vedotin 1deltacortene 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urogenital Neoplasms × ferumoxtran-10 × Clear all
NCT00147238 2012-08-07

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 3 charts
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡